Gallbladder cancer therapeutics pipeline is expected to witness increased growth in the future since very less number of drugs are available in the pipeline for the treatment of gallbladder cancer. There is an increase in awareness towards cancer treatments, increasing demand for safe and effective medicines, rising healthcare expenditure and technological advancements are supporting the growth of the gallbladder therapeutics pipeline.
According to National Cancer Institute, a part of the U.S. National Institutes of Health, gallbladder cancer is a rare disease in which malignant cells are found in the tissues of the gallbladder. The gallbladder is a pear-shaped organ that lies just under the liver in the upper abdomen. The gallbladder stores bile, a fluid made by the liver to digest fat. When food is being broken down in the stomach and intestines, bile is released from the gallbladder through a tube called the common bile duct, which connects the gallbladder and liver to the first part of the small intestine. Women and native American are at higher risk for the gallbladder cancer due to estrogen replacement therapy and oral contraceptive use. The detection of the gallbladder cancer is complex until it has reaches its advanced stage and shows symptoms. Only about 1 of 5 gallbladder cancers is found in the early stages, when the cancer has not yet spread beyond the gallbladder.
The pipeline of gallbladder cancer therapeutics pipeline includes anti-PD-1 antibody BGB-A317. BeiGene, Ltd. is developing BGB-A317, a Phase I drug candidate that shows well-tolerated anti-tumor activity in gallbladder cancer and in other solid tumors. GlaxoSmithKline Plc plans to introduce a combination therapy of Gemcitabine-Pazopanib, which is currently in Phase II. Bayer AG plans to introduce a drug, copanlisib for treatment of gallbladder cancer, which is currently in Phase II clinical development. Eli Lilly and Company plans to introduce a drug LY2801653, which is also known as Merestinib. Merestinib is currently in Phase I clinical development against gallbladder cancer. Regorafenib which is in Phase II clinical development is also a pipeline drug from Bayer AG.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/gallbladder-cancer-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of gallbladder cancer therapeutics include 4SC AG, BeiGene Ltd., Eli Lilly and Company, Novartis AG and VasGene Therapeutics Inc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)